Literature DB >> 26209436

Use of data mining at the Food and Drug Administration.

Hesha J Duggirala1, Joseph M Tonning2, Ella Smith3, Roselie A Bright4, John D Baker5, Robert Ball6, Carlos Bell2, Susan J Bright-Ponte5, Taxiarchis Botsis6, Khaled Bouri4, Marc Boyer3, Keith Burkhart2, G Steven Condrey7, James J Chen8, Stuart Chirtel3, Ross W Filice4, Henry Francis2, Hongying Jiang9, Jonathan Levine4, David Martin6, Taiye Oladipo3, Rene O'Neill9, Lee Anne M Palmer5, Antonio Paredes10, George Rochester10, Deborah Sholtes10, Ana Szarfman2, Hui-Lee Wong9, Zhiheng Xu9, Taha Kass-Hout4.   

Abstract

OBJECTIVES: This article summarizes past and current data mining activities at the United States Food and Drug Administration (FDA). TARGET AUDIENCE: We address data miners in all sectors, anyone interested in the safety of products regulated by the FDA (predominantly medical products, food, veterinary products and nutrition, and tobacco products), and those interested in FDA activities. SCOPE: Topics include routine and developmental data mining activities, short descriptions of mined FDA data, advantages and challenges of data mining at the FDA, and future directions of data mining at the FDA. Published by Oxford University Press on behalf of the American Medical Informatics Association 2015. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  data mining; disproportionality analysis; pharmacovigilance

Mesh:

Year:  2015        PMID: 26209436     DOI: 10.1093/jamia/ocv063

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  27 in total

1.  Neural Multi-Task Learning for Adverse Drug Reaction Extraction.

Authors:  Feifan Liu; Xiaoyu Zheng; Hong Yu; Jennifer Tjia
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

2.  Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions.

Authors:  C Lee Ventola
Journal:  P T       Date:  2018-06

3.  Learning predictive models of drug side-effect relationships from distributed representations of literature-derived semantic predications.

Authors:  Justin Mower; Devika Subramanian; Trevor Cohen
Journal:  J Am Med Inform Assoc       Date:  2018-10-01       Impact factor: 4.497

4.  Application of Natural Language Processing and Network Analysis Techniques to Post-market Reports for the Evaluation of Dose-related Anti-Thymocyte Globulin Safety Patterns.

Authors:  Taxiarchis Botsis; Matthew Foster; Nina Arya; Kory Kreimeyer; Abhishek Pandey; Deepa Arya
Journal:  Appl Clin Inform       Date:  2017-04-26       Impact factor: 2.342

5.  Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.

Authors:  Phuong Pham; Carmen Cheng; Eileen Wu; Ivone Kim; Rongmei Zhang; Yong Ma; Cindy M Kortepeter; Monica A Muñoz
Journal:  Pharmaceut Med       Date:  2021-09-02

6.  Improving the explainability of Random Forest classifier - user centered approach.

Authors:  Dragutin Petkovic; Russ Altman; Mike Wong; Arthur Vigil
Journal:  Pac Symp Biocomput       Date:  2018

7.  Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review.

Authors:  Faizan Mazhar; Vera Battini; Marco Pozzi; Elena Invernizzi; Giulia Mosini; Michele Gringeri; Annalisa Capuano; Cristina Scavone; Sonia Radice; Emilio Clementi; Carla Carnovale
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

8.  Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system.

Authors:  Lichy Han; Robert Ball; Carol A Pamer; Russ B Altman; Scott Proestel
Journal:  J Am Med Inform Assoc       Date:  2017-09-01       Impact factor: 4.497

Review 9.  No population left behind: Improving paediatric drug safety using informatics and systems biology.

Authors:  Nicholas P Giangreco; Jonathan E Elias; Nicholas P Tatonetti
Journal:  Br J Clin Pharmacol       Date:  2021-01-19       Impact factor: 3.716

10.  Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®).

Authors:  Jody L Green; Rebekkah S Robbins; Taryn Dailey-Govoni; Stephen F Butler
Journal:  J Pain Res       Date:  2021-06-15       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.